Wisconsin Center for Advanced Research

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis5 trials
• Obesity2 trials
• Crohn's disease1 trial
• Gastroparesis1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• AltruBio Inc.1 trial
• CinDome Pharma, Inc.1 trial
• InDex Pharmaceuticals1 trial

Running trials

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Chetan Mittal (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Chetan Mittal (principal investigator)

• Active, not recruiting

  Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

  NCT06109441· Phase 2· AltruBio Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Crohn's disease1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

  NCT05832151· Phase 2· CinDome Pharma, Inc.· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source